Septerna (SEPN) Competitors $12.34 +0.24 (+1.98%) Closing price 09/2/2025 04:00 PM EasternExtended Trading$12.33 -0.01 (-0.08%) As of 09/2/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock SEPN vs. AGIO, HRMY, OCUL, RXRX, IRON, BLTE, MESO, CGON, ANIP, and ADPTShould you be buying Septerna stock or one of its competitors? The main competitors of Septerna include Agios Pharmaceuticals (AGIO), Harmony Biosciences (HRMY), Ocular Therapeutix (OCUL), Recursion Pharmaceuticals (RXRX), Disc Medicine (IRON), Belite Bio (BLTE), Mesoblast (MESO), CG Oncology (CGON), ANI Pharmaceuticals (ANIP), and Adaptive Biotechnologies (ADPT). These companies are all part of the "pharmaceutical products" industry. Septerna vs. Its Competitors Agios Pharmaceuticals Harmony Biosciences Ocular Therapeutix Recursion Pharmaceuticals Disc Medicine Belite Bio Mesoblast CG Oncology ANI Pharmaceuticals Adaptive Biotechnologies Agios Pharmaceuticals (NASDAQ:AGIO) and Septerna (NASDAQ:SEPN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Do analysts recommend AGIO or SEPN? Agios Pharmaceuticals currently has a consensus target price of $56.33, suggesting a potential upside of 43.52%. Septerna has a consensus target price of $26.75, suggesting a potential upside of 116.77%. Given Septerna's stronger consensus rating and higher probable upside, analysts clearly believe Septerna is more favorable than Agios Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agios Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Septerna 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has better earnings and valuation, AGIO or SEPN? Agios Pharmaceuticals has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgios Pharmaceuticals$40.88M55.79$673.72M$11.003.57Septerna$1.08M509.37-$71.80M-$10.09-1.22 Does the media prefer AGIO or SEPN? In the previous week, Agios Pharmaceuticals had 5 more articles in the media than Septerna. MarketBeat recorded 8 mentions for Agios Pharmaceuticals and 3 mentions for Septerna. Agios Pharmaceuticals' average media sentiment score of 1.57 beat Septerna's score of 1.45 indicating that Agios Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Septerna 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is AGIO or SEPN more profitable? Agios Pharmaceuticals has a net margin of 1,590.42% compared to Septerna's net margin of -12,053.03%. Agios Pharmaceuticals' return on equity of -3.49% beat Septerna's return on equity.Company Net Margins Return on Equity Return on Assets Agios Pharmaceuticals1,590.42% -3.49% -3.23% Septerna -12,053.03%-31.52%-23.65% SummaryAgios Pharmaceuticals beats Septerna on 10 of the 13 factors compared between the two stocks. Get Septerna News Delivered to You Automatically Sign up to receive the latest news and ratings for SEPN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SEPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SEPN vs. The Competition Export to ExcelMetricSepternaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$539.48M$3.12B$5.74B$9.77BDividend YieldN/A2.28%6.66%4.50%P/E Ratio-1.2220.8682.9826.39Price / Sales509.37396.75537.51110.52Price / CashN/A43.5325.7028.92Price / Book1.468.1011.056.58Net Income-$71.80M-$53.35M$3.28B$265.84M7 Day Performance-2.30%-0.29%-0.17%-0.26%1 Month Performance1.06%9.18%8.35%5.82%1 Year PerformanceN/A10.11%53.92%22.47% Septerna Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SEPNSepterna1.9612 of 5 stars$12.34+2.0%$26.75+116.8%N/A$539.48M$1.08M-1.22N/APositive NewsAGIOAgios Pharmaceuticals4.3572 of 5 stars$37.17-0.3%$56.33+51.6%-14.5%$2.16B$36.50M3.38390News CoveragePositive NewsHRMYHarmony Biosciences4.2912 of 5 stars$37.32-0.3%$51.00+36.7%+3.1%$2.15B$772.53M12.05200Positive NewsOCULOcular Therapeutix3.6679 of 5 stars$12.15+2.4%$17.20+41.6%+44.0%$2.11B$63.72M-9.48230Positive NewsRXRXRecursion Pharmaceuticals2.105 of 5 stars$4.86+0.5%$7.00+44.2%-36.0%$2.11B$58.84M-2.73400Positive NewsGap DownIRONDisc Medicine3.2749 of 5 stars$59.98+1.0%$98.30+63.9%+20.8%$2.09BN/A-13.4230News CoveragePositive NewsBLTEBelite Bio2.6746 of 5 stars$64.71+1.7%$96.67+49.4%+34.3%$2.06BN/A-41.7510Positive NewsMESOMesoblast2.1924 of 5 stars$15.88+1.1%$18.00+13.4%+94.7%$2.03B$5.90M0.0080Gap DownCGONCG Oncology2.0447 of 5 stars$25.99+2.2%$55.27+112.7%-25.5%$1.98B$551K-14.6961ANIPANI Pharmaceuticals3.6754 of 5 stars$90.48+0.2%$84.75-6.3%+47.6%$1.96B$614.38M-117.50600Positive NewsADPTAdaptive Biotechnologies3.3071 of 5 stars$12.79+1.0%$12.38-3.3%+173.2%$1.95B$178.96M-15.60790Positive NewsGap Down Related Companies and Tools Related Companies AGIO Competitors HRMY Competitors OCUL Competitors RXRX Competitors IRON Competitors BLTE Competitors MESO Competitors CGON Competitors ANIP Competitors ADPT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SEPN) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Septerna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Septerna With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SEPN Stock Alerts